doxy-100
douglas pharmaceuticals limited - doxycycline hydrochloride 114mg (as docyclycine hyclate = doxycycline 100mg); - tablet - 100 mg - active: doxycycline hydrochloride 114mg (as docyclycine hyclate = doxycycline 100mg) excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry white y-1r-7000b
doxy-50
douglas pharmaceuticals limited - doxycycline hydrochloride 57mg (as docyclycine hyclate = doxycycline 50mg); - tablet - 50 mg - active: doxycycline hydrochloride 57mg (as docyclycine hyclate = doxycycline 50mg) excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry white y-1r-7000b
dp lotion-hc 1%
douglas pharmaceuticals limited - hydrocortisone 1%; ; - lotion - 1 % - active: hydrocortisone 1% excipient: carbomer cetyl alcohol glycerol lanolin liquid paraffin methyl hydroxybenzoate polysorbate 60 propyl hydroxybenzoate purified water sorbitan stearate trolamine
dp-anastrozole
douglas pharmaceuticals limited - anastrozole 1mg - film coated tablet - 1 mg - active: anastrozole 1mg excipient: hypromellose lactose monohydrate magnesium stearate opadry white y-1-7000 povidone sodium starch glycolate - treatment of advanced breast cancer in post-menopausal women.
fintral
douglas pharmaceuticals limited - finasteride 5mg; - tablet - 5 mg - active: finasteride 5mg excipient: hypromellose macrogol 8 stearate type 1 sodium starch glycollate type a lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate starch - fintral is indicated for the treatment and control of benign prostatic hyperplasia (bph) and for the prevention of urologic events to; · reduce the risk of acute urinary retention · reduce the risk of surgery including transuretheral resection of the prostate (turp) and prostatectomy fintral causes regression of the enlarged prostate, improved urinary flow and improves the symptoms associated with bph. patients with enlarged prostate are the appropriate candidates for therapy with fintral.
myaccord
douglas pharmaceuticals limited - mycophenolate mofetil 250mg; - capsule - 250 mg - active: mycophenolate mofetil 250mg excipient: croscarmellose sodium gelatin hyprolose indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose povidone purified talc sodium laurilsulfate tekprint black sw-9008 titanium dioxide water - myaccord is indicated for the prophylaxis of acute organ rejection in patients receiving allogeneic renal transplants.
myaccord
douglas pharmaceuticals limited - mycophenolate mofetil 500mg; - film coated tablet - 500 mg - active: mycophenolate mofetil 500mg excipient: croscarmellose sodium hyprolose magnesium stearate microcrystalline cellulose opadry purple 03b50110 povidone purified talc - for the prophylaxis of acute organ rejection in patients receiving allogeneic renal transplants.
ridal
douglas pharmaceuticals limited - risperidone 0.5mg; - film coated tablet - 0.5 mg - active: risperidone 0.5mg excipient: colloidal silicon dioxide hypromellose iron oxide red lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1-7000
ridal
douglas pharmaceuticals limited - risperidone 1mg; - film coated tablet - 1 mg - active: risperidone 1mg excipient: colloidal silicon dioxide hypromellose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1-7000
ridal
douglas pharmaceuticals limited - risperidone 2mg; - film coated tablet - 2 mg - active: risperidone 2mg excipient: colloidal silicon dioxide hypromellose iron oxide red lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1-7000 quinoline yellow